# AJMERA PHARMASURE PVT. LTD.

Assessment year 2013 - 2014

Financial year 2012 - 2013

	Particulars	Note No. as at 31-Mar-2013				
I.	EQUITY AND LIABILITIES			0.64.00.442.05		7 14 10 500 92
1	Shareholders' Funds			8,61,99,443.85	50 00 000 00	7,14,19,590.82
	(a) Share Capital	1	50,30,000.00		50,30,000.00	
	(b) Reserves and Surplus	2	8,11,69,443.85		6,63,89,590.82	
2	Non-Current Liabilities			4,99,363.00		16,900.00
	(a) Long-Term Borrowings	3	4,99,363.00			
	(b) Deferred Tax Liabilities (Net)		-		16,900.00	
3	Current Liabilities			3,24,34,049.00		62,78,408.12
	(a) Short-Term Borrowings	4	5,59,175.00		-	
	(b) Trade Payables	5	1,09,48,809.00		(88,96,416.88)	
	(c) Short-Term Provisions	6	2,09,26,065.00		1,51,74,825.00	
	Total			11,91,32,855.85	_	7,77,14,898.94
II.	ASSETS					
1	Non-Current Assets			7,82,64,050.96		1,02,20,597.93
	(a) Fixed Assets	7	49,56,566.02		45,35,148.02	
	(i) Tangible Assets		49,56,566.02		45,35,148.02	
	(b) Non-Current Investments	8	18,43,692.44		44,33,699.91	
	(c) Deferred Tax Assets (Net)	9	65,985.00		-	
	(d) Long-Term Loans and Advances	10	7,13,97,807.50		12,51,750.00	
2	Current Assets			4,08,68,804.89		6,74,94,301.01
	(a) Inventories		3,44,53,227.00		3,04,81,610.14	
	(b) Trade receivables	11	5,90,79,548.87		3,87,44,525.18	
	(c) Cash and Cash Equivalents	12	(8,07,80,940.69)		(2,50,21,877.70)	
	(d) Short-Term Loans and Advances	13	2,73,22,278.00		2,32,70,914.00	
	(e) Other Current Assets	14	7,94,691.71		19,129.39	
	Total			11,91,32,855.85		7,77,14,898.94

The Notes referred to above form an integral part of the Statement of Profit and Loss As per our report of even date

For Ajmera Pharmasure Pytikid.

For Rahul Jimulia & Associates Chartered Accountants

(Roules

Rahul C Jimulia

Proprietor Membership No.: 149855

Address: D-15, Ratnadeep Building, 60 Feet Road,

Bhayandar West.

Place Date

: Mumbai : 2-Sep-2013 Director/Auth. Sign.

(Director)

For and On behalf of the Board

### Ajmera Pharmasure Pvt Ltd

### Statement of Profit and Loss for the year ended 31-Mar-2013

In ₹ (Rupees)

	Particulars	Note No.	1-Apr-2012 to 31-Mar-2013	1-Apr-2011 to 31-Mar-2012
1	Revenue from Operations	15	32,78,23,025.29	17,31,96,852.00
II	Other Income	16	1,05,26,162.00	71,37,977.37
Ш	TOTAL REVENUE (I + II)		33,83,49,187.29	18,03,34,829.37
IV	EXPENSES			
	Purchases of Stock-in-Trade		29,31,59,387.00	16,44,10,972.45
	Changes in Inventories	17	(39,71,616.86)	(26,71,323.02)
	Employee Benefit Expenses	18	32,33,546.00	26,94,949.00
	Finance Costs	19	50,58,594.26	(54,469.40)
	Depreciation and Amortization Expenses		10,05,042.00	9,96,149.51
	Other Expenses	20	2,10,51,887.86	86,68,413.35
	TOTAL EXPENSES		31,95,36,840.26	17,40,44,691.89
٧	Profit before Exceptional and Extraordinary Items and Tax (III-IV)		1,88,12,347.03	62,90,137.48
VI	Exceptional Items		¥	-
VII	Profit before Extraordinary Items and Tax		1,88,12,347.03	62,90,137.48
VIII	Extraordinary Items		-	-
ΙX	Profit Before Tax		1,88,12,347.03	62,90,137.48
х	Tax Expense		(40,32,494.00)	-
	Current Tax		(41,15,379.00)	-
	Deferred Tax		82,885.00	-
ΧI	Profit/(Loss) for the period from Continuing Operations(IX-X)		1,47,79,853.03	62,90,137.48
XII	Profit/(Loss) from Discontinuing Operations		- //	-
XIII	Tax Expense of Discontinuing Operations		- !	2
XIV	Profit/(Loss) from Discontinuing Operations (after tax)(XII-XIII)		- :	-
χv	Profit(Loss) for the Period(XI+XIV)		1,47,79,853.03	62,90,137.48
XVI	Earnings per Equity Share			
	-Basic		293.83	125.05
	-Diluted		293.83	125.05

MUMBA

The Notes referred to above form an integral part of the Statement of Profit and Loss As per our report of even date

For Rahul Jimulia & Associates Chartered Accountants

Chilyna

Rahul C Jimulia

Proprietor

Membership No.: 149855

Address : D-15, Ratnadeep Building, 60 Feet Road,

Bhayandar West.

Place : Mumbai Date : 2-Sep-2013 For and On behalf of the Soard

Director/Auth Sign.

(Director)

### Ajmera Pharmasure Pvt Ltd

### **Share Capital**

In ₹ (Rupees) Note No: -1(a)

Particulars	as at 31	Mar-2013	as at 31-Mar-2012			
	Number of	Amount	Number of	Amount		
	Shares		Shares			
Authorised Share Capital						
Equity Shares of ₹ 100.00 each	150000	15000000.00	150000	15000000.00		
Total	150000	15000000.00	150000	15000000.00		
Issued Share Capital						
Equity Shares of ₹ 100.00 each	50300	5030000.00	50300	5030000.00		
Total	50300	5030000.00	50300	5030000.00		
Subscribed and fully paid						
Eguity Shares of ₹ 100.00 each	50300	5030000.00	50300	5030000.00		
Total	50300	5030000.00	50300	5030000.00		
Total	50300	5030000.00	50300	5030000.00		

Note No: -1 (b)

Shares in the company held by other company

Particulars	as at 31	-Mar-2013	as at 31-Mar-2012			
	Number of Shares	Amount	Number of Shares	Amount		
Equity Shares Richie Rich Resorts Ltd, Not Related.	5300	530000.00	5300	530000.00		

Note No: -1 (c)
Shareholders holding more than 5% of Share

Particulars	as at 31	-Mar-2013	as at 31-Mar-2012		
	Number of Shares	% of Holding	Number of Shares	% of Holding	
Richie Rich Resorts Ltd	5300	10.54 %	5300	10.54 %	
K H Ajmera (HUF)	2800	5.57 %	2800	5.57 %	
MUMBAI EST	,	For Ajmera F	and 6	e Pvt. Ltd. e	

### **Reserves and Surplus**

Note No - 2.1

in ₹ (Rupees)

Particulars	as at 31-Mar-2013	as at 31-Mar-2012
Securities Premium Account		
Closing balance	4770000.00	4770000.00
Surplus		
Opening Balance	61619590.82	55329453.34
(+) Net profit/(Net loss) for the Current Year	14779853.03	6290137.48
(-) Profit & Loss Appropriation A/c	0.000	0.000
Closing balance	76399443.85	61619590.82
Total	81169443.85	66389590.82

### Long-Term Borrowings

Note No - 3 . 1

In ₹ (Rupees)

		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
Particulars	as at 31-Mar-2013	as at 31-Mar-2012						
Secured								
Term Loans								
From banks								
ICICI Car Loan	499363.00	0						
Total	499363.00	0						

### **Short-Term Borrowings**

Note No -4.1

In ₹ (Rupees)

11010 110		iii ( (itapees)
Particulars	as at 31-Mar-2013	as at 31-Mar-2012
Unsecured		
Loans and advances from related parties		
Ajmera Commodities & Derivatives Pvt Ltd	559175.00	
Total	559175.00	

### **Trade Payables**

NOTE - 5

In ₹ (Rupees)

NOTE - 3	in a (Rupees)						
Particulars	as at 31-Mar-2013 as at 31-						
Others							
Mahalaxmi Logistic	-18335.000						
Silis Labs Pvt Ltd	-13034.000						
Sundry Creditors	10980178.00	-8896416.880					
Grand Total	10948809.00	-8896416.880					

### **Short-Term Provisions**

NOTE - 6

In ₹ (Rupees)

		m / (Nupees)
Particulars	as at 31-Mar-2013	as at 31-Mar-2012

### **Provision for Employee Benefits**

Salary and Reimbursements

Directors Salary Payable

Salary Payable

250000.00

1000000.00

204631.00

123971.00



For Ajmera Pharmasure Pvt. Ltd.

Director/Auth. Sign.

Grand Total	20926065.00	15174825.00
Vat Payable		<u>26611</u> 8.00
VAT (MP) Payable	1525324.00	
Telephone Exp Payable	1608.00	945.00
TDS Payable - Professional Fees	13034.00	
Tds Payable(Contractor)	19406.00	
Tds Payable(Brokerage & Commission)	435776.00	10065.00
Provison for Taxation(F.Y 07-08)	690933.00	690933.00
Provision for Taxation ([A.Y.2013-14)	4115379.00	
Provision for Taxation(F.Y. 09-10)	2222937.00	2222937.00
Provision for Taxation(F.Y. 08-09)	1462491.00	1462491.00
Provision for MAT (AY 2012-13)	1087377.00	1087377.00
Provision for Mat(A.Y 2011-12)	8208590.00	8208590.CO
Provision for Audit Fees	30000.00	20000.00
Professional Fees Payable		18000.00
Interest Payable	24589.00	
Entry Tax (MP) Payable	361133.00	
Cst Payable	63323.00	63398.00
Commission Payable	165523.00	
Brokerage Payable	44011.00	
Others		

For Ajmera Pharmasure Pyr. Ltd.



Director/Auth. Sign.

# M/s. AJMERA PHARMASURE PVT. LTD.

# SCHEDULE OF FIXED ASSETS AS ON 31.03.2012

(Note No. 07)

NET BLOCK	CLOSING	1278094.41	00.00	690746.00	62806.05	251259.00	217371.00	25000.00	3965.00	1414.00	63868.44	5963.62	1874578.50	481500.00	4956566.02	No. Days 259.00 104.00 180.00
NET B		127		)69	62	25.	21.	52	ň		- 63 	Ϋ́O	187	48	496	
	TOTAL	1362695.59	313633.00	158112.00	196147.95	251595.00	196719.00	00.00	9978.00	6256.00	18251.56	37636.38	669053.50	53500.00	3273577.98	Year End 31/03/2013 31/03/2013 31/03/2013
	C.Y.	446496.00	2585.00	158112.00	17330.00	55529.00	48039.00	0.00	641.00	229.00	10319.00	3975.00	208287.00	53500.00	1005042.00	Purchase Date 15/C7/2012 17/12/2012 02/10/2012
	Net Block	1724590.41	9983.00	848858.00	30136.05	306788.00	265410.00	25000.00	4606.00	1643.00	74187.44	9938.62	2082865.50	535000.00	5919006.02	
NO.	DEPRECIATION TO DATE	916199.59	311048.00	00.0	178817.95	196066.00	148680.00	00:00	9337.00	6027.00	7932.56	33661.38	460766.50	00.00	2268535.98	
DEPRECIATION	DEPRECIATION RATE	25.89%	25.89%	25.89%	40.00%	18.10%	18.10%	%00.0	13.91%	13.91%	13.91%	40.00%	10.00%	20.00%		Depreciation 158112.00 5778.00 53500.00
	AS AT 31/03/2013	2640790.00	313633.00	848858.00	258954.00	502854.00	414090.00	25000.00	13943.00	7670.00	82120.00	43600.00	2543632.00	535000.00	8230144.00	Days 259.00 104.00 180.00
GROSS BLOCK	ADDITION	00.0	-7398.00	848858.00	50000.00	00.0	00.00	00:00	00:00	00.0	00.00	0.00	0.00	535000.00	1426460.00	Rate 25.89% 40.00% 20.00%
	AS AT 01/04/2012	2640790.00	321031.00	00:00	208954.00	502854.00	414090.00	25000.00	13943.00	7670.00	82120.00	43600.00	2543632.00	0.00	6803684.00	CostWDV 848858.00 50000.00 535000.00
	PARTICULARS	CAR	CAR 9868	CAR (1-20)	COMPUTER	FURNITURE	REFIGERATOR	OFFICE PREMISES	FAX MACHINE	USB CARD READER	ELECTRONICS EQUIPMENT	SAMSUNG PRINTER	BHIWANDI GODOWN (BLDG.)	GENERATOR		CAR (I-20) COMputer GENERATOR
	MUMBAI Director/Auth. Sign.															



### **Non-Current Investments**

NOTE - 8		In ₹ (Rupees)
Particulars	as at 31-Mar-2013	as at 31-Mar-2012
Other Investments		
Investments in equity instruments		
Richie Rich Resort Ltd	500000.00	500000.00
Shares EPIC Enzyme Phar	2191.70	2191.70
Shares of IFCI	160859.49	160859.49
Shares of IOL Chemicals & Pharma. Ltd		2317785.19
Shares of Jaysynth Dye Chem	113050.00	113050.00
Shares of Praneta Industries Ltd	1063591.25	1063591.25
Shares of Souther & Steel Co.Ltd Coverted Jsw Steel		264841.83
Shares of Steel Authority of India		7380.45
Shares Silverline Animaton	4000.00	4000.00
Grand Total	1843692.44	4433699.91
Deferred Tax Assets (Net)		
NOTE - 9		In ₹ (Rupees)
Particulars	as at 31-Mar-2013	as at 31-Mar-2012
Deferred Tax Asset	65985.00	

Long-Term	Loans	and	Advances
NOTE - 10			

NOTE - 10		In ₹ (Rupees)
Particulars	as at 31-Mar-2013	as at 31-Mar-2012
Other loans and advances		
Unsecured, considered good		
Abhishek Organics	1200000.00	
Advance to Supplier	19301057.50	
Agarwal Pharmaceuticals	500000.00	500000.00
Bappalal Amulakha Zota(HUF)	224250.00	224250.00
Govind Laboratories Ltd		400000.00
IOL Chemicals & Pharmaceuticals	50000000.00	
Nipul Sanghavi	172500.00	117500.00
Vishnu Chikne		10000.00
Grand Total	71397807.50	1251750.00

### Trade receivables

**Grand Total** 

NOTE - 11		In ₹ (Rupees)
Particulars	as at 31-Mar-2013	as at 31-Mar-2012
Outstanding for more than 6 months from the due date Unsecured, considered good Sundry Debtors	59079548.87	38744525.18
Grand Total	59079548.87	38744525.18

MUMBAI MUMBAI MIN MANAJADANIAN AND MANAJ

For Ajmera Pharmasure Pytl Ltd.

65985.00

# Cash and Cash Equivalents NOTE - 12

NOTE - 12 Particulars	as at 31-Mar-2013	In ₹ (Rupees as at 31-Mar-2012
'articulars	as at 31-Mar-2013	as at 31-Mar-2012
Balances with banks		
In Current Account		
Citi Bank	2263168.62	61668.62
Hdfc Bank	-28761446.140	115616.30
lcici Bank	1820.41	783.99
Union Bank of India(103)	-59476798.180	-25721690.180
Union Bank of India(234)	52778.74	52778.74
Union Bank of India(484)	5113962.34	98064.34
Cash on hand		
Cash-in-hand		
Cash	25573.52	370900.49
Grand Total	-80780940.690	-25021877.700
Short-Term Loans and Advances		_
NOTE - 13		In ₹ (Rupees
Particulars	as at 31-Mar-2013	as at 31-Mar-2012
Other Loans and Advances		
Unsecured, considered good		
Advance Tax (AY 2012-13)	350000.00	350000.00
Advance Tax (A.Y.2013-14)	2500000.00	
Mat Credit Receivable(A.Y.2011-12)	8208590.00	8208590.00
MAT Credit Receivable (AY 2012-13)	1087377.00	1087377.00
Self Assessment Tax	621240.00	
TDS	14742.00	
Tds Receivable (A.Y 2007-08)	10969.00	10969.00
Tds Receivable(A.Y. 2008-09)	731857.00	7318 <b>57</b> .00
Tds Receivable(A.Y. 2009-10)	1435034.00	1435034.00
Tds Receivable A.Y. 2010-11)	2290792.00	2290792.00
Tds Receivable(A.Y. 2011-12)	9004713.00	9004713.00
TDS Receivable (AY 2012-13)	151582.00	151582.00
TDS Receivable (A.Y.2013-14)	915382.00	707002.00
Grand Total	27322278.00	23270914.00
Other Current Assets NOTE - 14		In ₹ (Rupees)
Particulars	as at 31-Mar-2013	as at 31-Mar-2012
	do di o i Mai 2010	do di o i Mai 2012
Ajmera Associates Ltd	-4279.290	-29790.610
Commission Receivable		27106.00
Electricity Deposite	9600.00	9600.00
Godown Deposite	5000.00	5000.00
nterest Recivable	783871.00	
Miscellaneous Expenditure		6714.00
Atnl Deposit	500.00	500.00
Grand Total	704604-74	40420.20
	For Ajmera Pha	rmasure Pvt. Li
MARIA	For Ajmera Pha	AL
WALL STORY		mar 6 M

BAI ES

Director/Auth. Sign.

## AJMERA PHARMASURE PVT. LTD.

Detail of Sundry Creditors as on 31-03-2013

Sr. No.	Sundry Creditors	Amount
1	AARAMBH'LIFE SCIENCE	11,50,286.00
.2	GRANTH PHARMACEUTICALS PVT. LTD.	2,99,084.00
3	K D LIFE SCIENCES	5,00,000.00
4	PREMIER DRUG HOUSE	37,229.00
5	RUCHITA PHARMACHEM	2,15,665.00
6	SNEHA MEDICARE PVT. LTD.	84,40,429.00
7	RAYCHANDRA & CO.	3,37,485.00
	Closing Totals :	1,09,80,178.00

Advance Paid to Supplier

	Sundry Creditors	Amount
1	ABHINAV ORGANIC PRIVATE LIMITED	2,03,179.00
2	ABHISHEK CHEMICALS	7,198.00
3	ABHISHEK ORGANIC (P) LTD.	29,79,500.00
4	IOL CHEMICALS & PHARMACEUTICALS LTD.	1,54,93,869.00
5	J.R. PHARMA	6,17,311.50
		1,93,01,057.50

## AJMERA PHARMASURE PVT. LTD.

Detail of Sundry debtors as on 31-03-2013

Sr. No	Sundry Debtors O	THERS	MORE THAN 6
1	A.V.R.TRADECHEM (INDIA) PVT. LTD	67,450.00	
2	ABHISHEK ORGANIC PVT. LTD.	1,85,905.00	
3	ABIL CHEMPHARMA PVT. LTD.	1,02,900.00	
4	ADD BIOTEC	3,46,500.00	_
5	AGOG PHARMA LTD.	(1,891.00)	
6	AGRON REMEDIES PVT. LTD.	17,831.00	
, ,	ALÇON LABORATORIES	31,107.00	
8	AMCURE CHEMICALS	14,53,742.00	
8	ANCHOR PHARMA PVT.LTD	3,02,399.00	
10	APPLE PHARMA	62,213.00	
11	AQUATIC REMEDIES PVT. LTD.	16,57,141.00	
12	ASUWALDI PHARMACEUTICAL\$	1,52,999.00	
13	ASUWALDI PHARMACEUTICALS.	1,83,315.00	
14	ATUL PHARMACEUTICALS (GUJ)	1,08,120.00	50.00
	BASE PHARMACY (INDIA)	2,682.00	
16	BOMBAY TABLET MFG. CO. PVT.LTD	24,282.00	
17	CENTRAL DRUG HOUSE.	9,42,325.00	
18	CLEVUS LIFÉ SCIENCE	99,460.00	
19	CYANO PHARMA (P ) LTD	3,00,071.00	
20	D.P.B. ANTIBIOTICS	3,86,400.00	
21	DANA PHARMACEUTICALS PVT. LTD.	1,04,325.00	
22	DEEP PHARMA CHEM .	1,38,600.00	
23	DEEPEN DRUGS	59,471.00	
24.	DOLPHIN INTERNATIONAL	3,11,067.00	
25	DOVE CHEMICALS LTD.	81,745.00	
26	ELCON DRUGS & FORMULATIONS LTD	17,74,082.00	
27	ELYSIUM PHARMACUTICALS LTD.		22545.18
28	EMBIOTIC LABORATORIES PVT LTD	15,650.00	
29	ENICAR PHARMACEUTICALS PVT. LTD.	31,157.00	
30	FLOURISH PHARMA	13,93,174.00	
31	GREENLIFE PHARMACEUTICALS LTD.	76,80,197.69	

Sr. No	Sundry Debtors	OTHERS	MORE THAN 6
32	GRIPIL PHARMACEUTICALS PVT. LTD.	7,55,587.00	
33	HAB PHARMACEUTICALS & RESEARCH LTD.	1,47,671.00	
	HARESH CHEMICALS	3,10,418.00	
	HEMLIN CHEMICALS	2,48,334.00	
	HIMANSHU PHARMACEUTICALS PVT. LTD.	5,92,000.00	
	HIND RASAYAN	62,084.00	
38	HITEN PHARMA CHEM	31,042.00	
	JUHARMAL & CO.	1,44,738.00	
40	KETAN PHARMA	21,72,010.00	
	KWALITY PHARMACEUTICALS PVT. LTD.	7,33,250.00	
42	LAVINA PHARMACEUTICALS PVT LTD	1,73,100.00	
43	LEBEN LABORATORIES PVT. LTD.	16,93,533:00	
44	MAHADEV MEDICAL AGENCY	6,82,500.00	
45	MANEESH PHARMACEUTICALS LTD. UNIT -1	1,55,209.00	
46	MATINS HEALTHCARE	1,33,160.00	
47	MAXWELL LIFE SCIENCES P.LTD	35,43,344.00	
48	MCW HEALTHCARE PVT. LTD.	5,01,635.00	
49	MEDIBIOS LABORATORIES P.LTD.	4,97,418.00	
50	MEDIROSE DRUGS AND PHARMACEUTICALS	2,95,158.00	
51	MEHTA MEDICARE PVT. LTD.		1018
52	MEHUL TRADING CO.	1,24,297.00	
53	MEPRO PHARMACEUTICALS PVT LTD (UNIT-II).	7,28,948.00	
54	MERCURY HEALTHCARE PVT. LTD	3,41,460.00	
55	MIHIKA PHARMACEUTICALS	1,86,960.00	
	MUNDRA ENTERPRISES	30,315.00	
	N.J.PHARMA	2,73,000.00	
	NEMI ENTERPRISE	7,951.00	
	NEMI PHARMA CHEM	3,11,067.00	
	NEWTON CHEMICALS	69,300.00	
61		11,18,801.00	
62	ORGANIX	2,96,254.00	
	OZONE PHARMACEUTICALS LTD	7,00,693.00	
	P.R. PHARMA SOURCE (P) LTD	20,81,100.00	
	PARAM PHARMA CHEM		32549
	PARK PHARMACEUTICALS	3,80,765.00	320.0
	PASSIM MEDI CHEM AGNECIES.	75,631.00	
	PESINO PHARMACEUTICALS PVT.LTD.	39,519.00	
	PRAGATI CHEM-IMPEX PVT. LTD	1,24,167.00	
	PRASHI PHARMA PVT, LTD.	33,24,242.00	
	PREET INTERNATIONAL PVT. LTD.	29,587.00	;
	PREMIER DRUG HOUSE	1,21,170.00	
	PRIME PHARMACHEM	3,07,716.00	
	PROBIOS HEALTHCARE	2,95,110.00	
	PSG PHARMA	75,322.00	_
	QUALITEK PHARMACEUTICALS	70,022.00	186474
	QUEST LABORATORIES PVT LTD	8,99,304.00	100474
	QUIXOITIC HEALTHCARE	86,831.00	
	RAJAT PHARMACHEM LTD	7,85,019.00	
	RAJDEEP PHARMACEUTICALS	1,00,407.00	
	RYCE YASH INDIA	(604.00)	
	SAMIR PHARMA.	9,78,351.00	
	SAMSON LABORATORIES PVT. LTD.		
		2,98,113.00	
	SCHON PHARMACEUTICALS LIMITED	1,56,761.00	
	SCOTT-EDIL PHARMACIA LTD.	15,68,602.00	
	SERVO SANITUS REMEDIES	17,73,000.00	
	SHALIBHADRA INTERNATIONAL	3,72,501.00	
	SHREECHEM PHARMACEUTICALS PVT.LTD.	8,574.00	
	SIDDHI PHARMA CHEM	1,37,550.00	, -
1 00	SIDDHI VINAYAK PHARMA	68,250.00	

Ortered Acco

Sr. No	Sundry Debtors	OTHERS	MORE THAN 6 MONTHS
91	SNEHA MEDICARE PVT.LTD.	30,990.00	
92	SOLUMED PHARMA.	(40,917.00)	
93	SREETECH PHARMA (INDIA) PVT LTD	46,899.00	
94	SUN LIFE SCIENCES	2,95,155.00	
95	SUNWAYS LABORATORIES PVT. LTD.	11,016.00	
96	SWASTIK PHARMACEUTICALS	14,27,922.00	
97	SWETA PHARMA PVT. LTD.	60,585.00	
98	TIWARI CHEMICALS	4,17,127.00	
99	TURAKHIA BROTHERS	65,276.00	
100	UKAY REMEDYS PVT.LTD.	5,355.00	-
101	UNIBIOTECH FORMULATIONS	3,33,785.00	
102	UTSAV MULTITRADE	28,437.00	
103	VAISHALI PHARMA PVT.LTD.	2,73,315.00	
104	VAPI CARE PHARMA P. LTD.	30,263.00	
105	VARDHMAN EXPORTS	27,31,676.00	
106	VIKAS PHARMACEUTICAL LABORATORIES.	1,86,251.00	
107	WILCURE REMEDIES PVT. LTD.	11,382.00	
108	YASH ENTERPRISES	60,585.00	
109	ZEE LABORATORIES	5,99,040.00	
110	ZEST PHARMA	31,00,176.00	
	Total	5,88,36,962.69	2,42,586.18



### **Revenue from Operations**

NOTE - 15	1-Apr-2012 to 31-Mar-2013	In ₹ (Rupees) 1-Apr-2011 to 31-Mar-2012
Particulars	1-Apr-2012 to 31-War-2013	1-Apr-2011 to 31-ivial-2012
Sale of Products	327284727.29	173196852.00
Export Sales	43114583.69	
Local Sales	284170143.60	
Sales		173196852.00
Other Operating Revenues	538298.00	
Direct Incomes	538298.00	
Export Icentive	538298.00	
Grand Total	327823025.29	173196852.00
Other Income		
NOTE - 16		In ₹ (Rupees)
Particulars	1-Apr-2012 to 31-Mar-2013	1-Apr-2011 to 31-Mar-2012
<del></del>		
Interest Income		
Interest Received	7789956.00	1266056.00
Dividend Income		
Dividend Received	6615.00	7391.50
Other Non-Operating Income		
Indirect Incomes		
Bad Debt Recovery		851841.00
Commission Recd		136000.00
Discount Received	2094761.00	810872.00
Other Income	18500.00	
Rate Diff	203900.00	4280386.60
Net gain on foreign currency transaction and translation (other than considered for finance cost)		
Foreign Exchange Difference	412430.00	-214569.730
Grand Total	10526162.00	7137977.37
Changes in Inventories		
NOTE - 17		In ₹ (Rupees
Particulars	1-Apr-2012 to 31-Mar-2013	1-Apr-2011 to 31-Mar-2012

NOTE - 17		In ₹ (Rupees)
Particulars	1-Apr-2012 to 31-Mar-2013	1-Apr-2011 to 31-Mar-2012
Stock-in-Trade -Opening Balance Less: Closing Balance	30481610.14 34453227.00	
Grand Total	-3971616.860	-2671323.020

# Employee Benefit Expenses

NOTE - 18		In ₹ (Rupees)
Particulars	1-Apr-2012 to 31-Mar-2013	1-Apr-2011 to 31-Mar-2012
Salaries and Wages		
Directors Remuneration	1200000.00	1000000.00
Diwali Bonus	91435.00	88531.00
Salaries	1703611.00	1426418.00
Staff Welfare Expenses		
Staff Welfare Exp	238500.00	180000.00
Grand Total	3233546.00	2694949,00

For Ajmera Pharmasure Pvt. Ltd.

Director/Auth. Sign.

### **Other Expenses**

NOTE - 20 In ₹ (Rupees)

NOTE - 20	1 Apr 2012 to 24 Mar 2012	In ₹ (Rupees)
Particulars	1-Apr-2012 to 31-Mar-2013	1-Apr-2011 to 31-Mar-2012
Net loss on sale of investment		
Loss on Sale of Share - Long Term	286866.32	849904.93
Payment to Auditors		
As Auditor		
Audit Fees	30000.00	23140.00
Rent		
Godown Rent	151750.00	155000.00
Rent Paid	10417.00	12311.00
Insurance		
Insurance	200377.00	159944.00
Rates and taxes (excluding taxes on income)		
CST Paid	976095.00	740894.00
Custom Duty Paid	354277.00	425438.00
Entry TAX (MP)	361133.00	
Lst Paid(Vat)	5192372.00	3410517.00
VAT Paid (MP)	1525324.00	
Miscellaneous expenses		
Advertising Expenses	98000.00	97000.00
Bad Debts	91606.00	
Bank Charges	25043.48	438346.35
Bank Charges - Export	25970.04	
Bank Charges(Import)	102996.41	17102.64
Brokerage Paid	51590.00	48368.00
Business Promotion Expenses	224720.00	
Carriage Inward	77990.00	9100.00
Clearing Charges	8854.00	
Commission Paid	5380334.00	1417166.00
Conveyance & Car Expenses	49654.00	,,,,,,
Difference and Shortages	184255.73	1956.60
Discount		15657.00
Donation	505000.00	20000.00
Electricity Charges	387202.00	81472.00
Freight Paid	1836466.60	39208.00
General Expenses	822046.08	211130.00
Goods Lost	985900.00	277700.00
Mahanagar Gas Expense	6542.00	
Maintenance Charges	105238.00	25920.00
Membership & Subscription	26888.00	48000.00
Preliminary Expenses Written Off	6714.00	3356.00
Printing & Stationery	17372.00	22690.00
Processing Fees	5515.00	22000.00
Professional Fees	286762.00	202705.00
ROC Fees		16800.00
Security Transaction Tax(Del.STT)	4624.20	3472.83
Software Maintanance	7500.00	7500.00
Sponsorship	7,300,00	20000.00
Telephone Charges	41848.00	12604.00
Testing & Laboratories	130339.00	12004.00
Travelling Expense	466306.00	121710 00
Grand Total	21051887.86	131710.00
Gianu iotai	21051887.86	8668413.35

For Ajmera Pharmasure Pvt. Ltd.



### M/S. AJMERA PHARMASURE PVT. LTD.

### ASSESSMENT YEAR: 2013-14

### NOTES TO THE ACCOUNTS

- 21. The Assessee is following the Mercantile System of Accounting, and the same system is regularly followed by the Assessee.
- 22. Depreciation is provided in the accounts at the rates allowable under Schedule XIV of the Companies Tax Act, 1956 under W.D.V. method.
- 23. Previous years figures have be regrouped /reclassified wherever necessary to confirm to the current year groupings based on Revised Schedule VI format prescribed under the Companies Act, 1956.

24. <u>Auditor's Remuneration</u> <u>31-03-2013</u> <u>31-03-2012</u> 20000

25. During the year under audit none of the employee were paid remuneration of Rs.1,44,000/- per annum or Rs.12000/- per month in respect of the part of the year.

### 26. Taxation

(i) <u>Current Tax</u>

Provision for Income Tax is determined in accordance with the provisions of Income Tax Act, 1961.

- (ii) <u>Deferred Tax</u>
  Deferred Tax Asset has been recognized in the books at Rs.82,885/-
- 27. Earnings Per Share

Earnings per share is calculated as required in Accounting Standard 20 issued by the Institute of Chartered Accountants of India and is as under:

MIMEA

	Particulars	Year Ending	Year Ending
		31-03-2012	31-03-2012
1	Net Profit After Tax	1,47,79,853.03	62,90,137.48
2	Number of Shares	50,300	50,300
3	Basic & Diluted Earnings Per Share	293.83	125.05
4	Weighted Average Earnings Per Share	293.83	125.05

As per our report of even date For RAHUL JIMULIA & ASSOCIATES Chartered Accountants

For and on Behalf of the Board of Directors

AJMERA PHARMASURE PVT, LTD

(Rahul C Jimulia) (Proprietor)

Membership No.149855 Firm Registration No.:

Place: MUMBAI Date: 02-09-2013 (Director)

### AJMERA PHARMASURE PVT. LTD.

63/67, Carmellos Building, Pathak Wadi, Mumbai – 400002

### **DIRECTOR'S REPORT**

To,

The Members,

Your Directors have great pleasure in presenting Audited Balance Sheet as at 31<sup>st</sup> March 203 and audited Profit & Loss Account for the year ended on that date together with the report of Auditors thereon.

### **DIVIDEND:**

The Company has made Profit of Rs. 1,47,79,853/- for the current year. But in order to conserve resources the directors have not recommended any dividend.

### **PUBLIC DEPOSITS:**

The Company has not accepted any deposits from the public during the year under section 58A of the Companies Act, 1956.

### PERSONNEL:

There is no employee in the company who is covered u/s 217(2A) of the Companies Act, 1956.

### **EMPLOYEE RELATIONS:**

Your Directors wish to sincerely thank all the employees for the cordial relation and excellent and valuable services rendered by them to the Company. Management recognizes that the Company's human resources represent a vital contribution to its success, both past and future, and will continue its progressive policies to encourage excellence in professionalism both in individual and team spirit.

### **AUDITORS:**

M/s. Rahul Jimulia & Associates, Chartered Accountants, the retiring auditors are eligible for reappointment and offer themselves for the same.

Con.2

### AJMERA PHARMASURE PVT. LTD.

63/67, Carmellos Building, Pathak Wadi, Mumbai – 400002

:2:

### **DIRECTOR'S RESPONSIBILITY STATEMENT:**

Pursuant to Section 217 (2AA) of the Companies Λct, your Directors confirm that:-

- a) in the preparation of the annual account, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit or loss of the company for that period;
- c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) The directors had prepared the annual accounts on a going concern basis.

# CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNING AND OUTGO, RESEARCH AND DEVELOPMENT EXPENDITURE:

Your company has made export sales to the tune of Rs.4,31,14,584/- and earned Export Incentive to the tune of Rs.5,39,298/- in foreign exchange which are related to Export Sales and have gained on Rs.4,12,430/- towards foreign exchange on account of currency fluctuation..Except the above, there are no activities carried out by the company in relation to the above.

### **ACKNOWLEDGEMENTS:**

Your Directors wish to place on record their appreciation of the wholehearted cooperation and support received from the Company's Bankers, financial Institutions, Customers, Shareholders, Dealers and suppliers and look forward to maintain the same extent of co-operation cordiality, support and trust.

For Ajmera Pharmasure Pvt. Ltd.

(Director)

Place: Mumbai Dated: 02.09.2013

### RAHUL JIMULIA & ASSOCIATES

### **Chartered Accountants**

D-15, Ratnadeep Building, 60 Feet Road, Bhayandar West, Thane - 401 101.

### INDEPENDENT AUDITORS' REPORT

For the year ended March 31, 2013

To the Members of

AJMERA PHARMASURE PRIVATE LIMITED

### Report on the Financial Statements

We have audited the accompanying financial statements of AJMERA PHARMASURE PRIVATE LIMITED ("the Company") which comprise the Balance Sheet as at March 31,2013 and the Statement of Profit and Loss for the year then ended, and a summary of significant accounting policies and other explanatory information.

### Management's Responsibility for the Financial Statements

Management is responsible for the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting standards referred to in sub-section (3C) of section 211 of the Companies Act, 1956 ("the Act"). This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance ether the financial statements are free from material misstatement.

### Rahul Jimulia & Associates Chartered Accountants

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the management, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give a true and fair view in conformity with the accounting principles generally accepted in India

- I. In the case of Balance Sheet, of the state of affairs of the Company as at March 31,2013;
- II. In the case of Statement of Profit and Loss, of the profit for the year ended on that date

### Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2003 issued by the Central Government of India in terms of sub-section (4A) of section 227 of the Companies Act, 1956, we enclose in the Annexure, a statement on the matters specified in apply 4 and 5 of the said order.

### Rahul Jimulia & Associates Chartered Accountants

- 2) As required by Section 227(3) of the Act, we report that:
  - a) We have obtained all the information and explanations which, to the best of our knowledge and belief were necessary for the purpose of our audit;
  - b) In our opinion, proper books of account as required by law have been kept by the Company so as far as appears from our examination of the books;
  - c) The Balance Sheet and Statement of Profit and Loss dealt with by this report are in agreement with the books of account;
  - d) In our opinion, the Balance Sheet and Statement of Profit & Loss comply with the Accounting Standards referred to in sub-section (3C) of Section 211 of the Companies Act, 1956 to the extent applicable.
  - e) On the basis of the written representations received from the Directors as on March 31, 2013, and taken on record by the Board of Directors, we report that none of the directors are disqualified as on March 31, 2013 from being appointed as a director in terms of clause (g) of sub-section (1) of section 274 of the Companies Act, 1956.

For Rahul Jimulia and Associates Chartered Accountants

(Rahul C Jimulia)
Proprietor

Membership No. 149855 Firm Regn No: 134709W

Place: Mumbai Date: 02.09.2013

### RAHUL JIMULIA & ASSOCIATES

### **Chartered Accountants**

D-15, Ratnadeep Building, 60 Feet Road, Bhayandar West, Thane - 401 101.

### ANNEXURE

Re: Ajmera Pharmasure Private Limited

Referred to in paragraph 3 of our report of even date

- 1. (a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.
  - (b) All the assets have been physically verified by the management during the year and there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the company and the nature of its assets. There are no material discrepancies.
  - (c) The sale of assets during the year is not substantial; it does not affect the going concern of the company.
- 2. (a) The inventory has been physically verified during the year by the management. In our opinion, the frequency of verification is reasonable.
  - (b) The procedures of physical verification of inventories followed by the management are reasonable and adequate in relation to the size of the Company and the nature of its business.
  - (c) The company is maintaining proper records of inventory. No material discrepancies have been noticed on physical verification between the physical stocks and the book records.
- 3. (a) The Company has granted interest-free unsecured deposit in the nature of advance / loan to the following parties included in the register maintained under section 301 of the Companies Act, 1956 and / or to the companies under the same management fined their section 370(1B) of the Companies Act, 1956.

### Continuation Sheet

### Rahul Jimulia & Associates Chartered Accountants

Sr.No.	Name	Status	Maximum	Year End
			O/s	Balance
1	Ashish K Ajmera	Individual	185,690.00	
2	Ashjit Realties Pvt Ltd	Company	36,000,000.00	
3	Ashley Resorts Pvt Ltd	Company	1,000,000.00	
4	Dhruv A Ajmera	Individual	55,780.00	-
5	Jiten K Ajmera	Individual	455,420.00	
6	Kishore H Ajmera	Individual	79,450.00	
7	Kishore H Ajmera - FT	Individual	17,010.00	_
8	Manish K Ajmera	Individual	446,520.00	
9	Richie Rich Resorts Ltd	Company	95,999.00	
10	Riviera Resorts Pvt Ltd	Company	2,037,050.00	
	Total		40,372,919.00	

- (b) According to the information and explanations as given to us, terms and conditions of deposits given by the company to above parties are prima facie prejudicial to the interest of the company and its members in as much as no interest is received on the aforesaid deposits
- (c) According to the information and explanations as given to us, there is no stipulation as to repayment of deposit in the nature of advance / loan granted and since the same are interest-free, reporting on regularity of payment of interest does not arise.
- (d) According to the information and explanations as given to us, since there is no stipulation as to repayment of deposit in the nature of advance granted, there is no overdue amount of loans taken from or granted to companies, firms or other parties listed in the register maintained under section 301 of the Companies Act, 1956.
- (e) The Company has taken loan from 14 parties covered in the register maintained under Section 301 of the Companies Act, 1956. The maximum amount outstanding during the year was Rs. 7,63,16,455/- and the closing balance is

Rs.5,59,175/-

### **Continuation Sheet**

### Rahul Jimulia & Associates Chartered Accountants

Sr.No.	Name	Status	Maximum	Year End_
			O/s	Balance
1	Alpesh K Ajmera	Individual	758,280.00	<u> </u>
2	Ashwini Jiten Ajmera	Individual	1,500,000.00	_
3	Avani Jiten Ajmera	Individual	2,000,000.00	
4	Charmi Jasmin Ajmera	Individual	4,300,000.00	-
5	Jash Alpesh Ajmera	Individual	2,500,000.00	
6	Jasmin K Ajmera	Individual	17,499,000.00	_
7	Jesal M Ajmera	Individual	4,500,000.00	-
8	Jiten K Ajmera (HUF)	HUF	200,000.00	_
9	Kishore H Ajmera - HUF	HUF	15,000,000.00	
10	Manharlal H Ajmera	Individual	22,500,000.00	
11	Minal M Ajmera	Individual	2,000,000.00	
12	Reena Ajmera	Individual	2,000,000.00	
. 13	Ajmera Commodities & Derivatives Pvt Ltd	Company	559,175.00	559,175.00
14	Ajmera Associates Ltd	Company	29,790.61	4,279.29
	Total		76,346,245.61	563,454.29

- (f) Since there are no stipulations as to the rate of interest and other terms and conditions / repayment of principal amount no reporting is done on clause (f) & (g).
- 4. According to the information and explanations as given to us since there is no purchase of inventory or any sale of goods of any transaction of fixed assets during the financial year, the reporting on the adequacy of internal control procedures commensurate with the same is not done.

Rahul Jimulia & Associates

**Continuation Sheet** 

### Chartered Accountants

- 5. (a) Based on the audit procedures applied by us and according to the information and explanations provided by the management, we are of the opinion that the transactions that need to be entered into the register maintained under section 301 have been so entered.
  - (b) In our opinion and according to the information and explanations as given to us, there are no transactions made in pursuance of contracts or arrangements which require to be entered in the registers maintained under Section 301 and exceeding the value of five lakh rupees in respect of any party during the year and which should have been made at prices which are reasonable having regard to prevailing market prices at the relevant time.
- 6. In our opinion and according to the information and explanations given to us, the company has not accepted any deposits requiring compliance with the provisions of Sections 58A and 58AA of the Companies Act, 1956 and the Companies (Acceptance of Deposits) Rules, 1975 with regard to the deposits accepted from the public. No order has been passed by the Company Law Board, National Company Law Tribunal or the Reserve Bank of India or any other court.
- 7. As explained to us, the company does not have a formal internal audit system. But we are informed that the directors keep a daily check themselves.
- 8. In our opinion and according to the information and explanations as given to us, the company is not required to, by the Central Government, to maintain cost records under section 209(1)(d) of the Companies Act, 1956.
- 9. (a) In our opinion and according to the information and explanations as given to us, there are no undisputed statutory dues outstanding and payable under laws that apply to dues relating to provident fund, investor education protection fund, employees' state insurance, income-tax, sales-tax, wealth-tax, service tax custom duty, excise tax custom other statutory dues, as applicable to it.

### Rahul Jimulia & Associates Chartered Accountants

- (b) According to the information and explanations as given to us, no undisputed amounts payable in respect of income tax, wealth tax, service tax, sales tax, customs duty and excise duty were outstanding, as at March 31, 2013 for a period of more than six months from the date they became payable.
- (c) According to the records of the company, and according to the information and explanations given to us, there are no dues of sales tax, income-tax, Customs duty / wealth-tax, service tax, excise duty / cess which have not been deposited on account of any dispute.
- 10. In our opinion, the company does not have any accumulated losses as at the end of the financial year. The company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- 11. In our opinion and according to the information and explanations given to us, the company has not defaulted in repayment of dues to a financial institution, bank or debenture holders.
- 12. According to the information and explanations as given to us, and based on our examination of documents and records, the company has not granted any loans and advances on the basis of security by way of pledge of shares, debentures and other securities.
- 13. In our opinion and according to the information and explanations as given to us, the nature of activities of the Company does not attract any special statute applicable to chit fund and nidhi / mutual benefit fund / societies.
- 14. As explained to us, the company is not dealing in or trading in shares, securities, debentures and other investments as envisaged by the provisions of clause 4(xiv) of the Companies (Auditor's Report) Order, 2003. Accordingly, the provisions of clause 4(xiv) of the Companies (Auditor's Report) Order, 2003 are not applicable to the company.
- 15. According to the information and explanations as given to us, the company has not given any guarantee for loans taken by others from bank or financial institutions.
- 16. As explained to us towards purch short car.

### Rahul Jimulia & Associates Chartered Accountants

- 17. According to the information and explanations as given to us and on an overall examination of the balance sheet of the company as at March 31, 2013, we report that no funds raised on short term basis have been used for long term investments.
- 18. According to the information and explanations as given to us, the company has not made any preferential allotment of shares to parties and companies covered in the register maintained under section 301 of the Companies Act, 1956.
- 19. According to the information and explanations as given to us, during the period covered by our audit report, the company has not issued any debentures and hence creation of security in respect thereof does not arise.
- 20. According to the information and explanations as given to us, during the period covered by our audit report, the company has not made any public issue and hence no reporting on any end use of money raised is done, since not applicable.
- 21. According to the information and explanations given to us, we report that no fraud on, or by the company, has been noticed or reported during the course of our audit.

MUMBAI POR CONTROL OF CONTROL OF

For Rahul Jimulia and Associates Chartered Accountants

> (Rahul. C. Jimulia) Proprietor Membership No. 149855

Firm Regn No: 134709W

Place: Mumbai Date: 02.09.2013